Will there be rebound when using Nirmatrelvir/Ritonavir combination?
The U.S. Food and Drug Administration does not approve the nematrelvir/ritonavir tablet combination Paxlovid (Nirmatrelvir/Ritonavir) for treatment beyond 5 days. Additionally, the use of pre-exposure or post-exposure prophylaxis is not approved to prevent novel coronavirus infection. Drug resistance generally refers to the gradual weakening of the virus's effect on drugs, resulting in a decrease in the effectiveness of drug treatment.

NematrevirThe ritonavir/ritonavir tablet combination is an antiviral drug that works by blocking the growth and spread of the virus that causes coronavirus (new coronavirus infection) in the body. It is used to treat early new coronavirus infection (within 5 days after the onset of symptoms) and helps prevent more severe symptoms, hospitalization and death. Studies have shown that patients can reduce the risk of hospitalization by 88% if taken within 5 days of the onset of symptoms. The FDA analysis suggests that COVID rebound associated with symptoms and/or a positive viral test may be part of the natural history of the disease, regardless of whether the nematvir/ritonavir combination is taken, but that this rebound effect is not a new COVID infection or due to pacyclovir resistance.
NematrevirThe combination of nematvir/ritonavir tablets has been launched in China. Due to its short time on the market, it has not been included in the medical insurance. The domestic price has not yet been determined. The original drug of nematvir/ritonavir tablet combination marketed overseas, the specification is nematvir 150mg + ritonavir 100mg)*30 tablets per box, the price may be around 2,000 yuan (the price may fluctuate due to the exchange rate), India The price of each box of the generic Nematvir/Ritonavir tablet combination produced by the pharmaceutical factory may be around RMB 1,000 (the price may fluctuate due to the exchange rate). The ingredients of the two drugs are basically the same. For more drug information and specific prices, please consult Yaode Medical Consultant.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)